CrisprBits is a biotech startup based in Bengaluru, India, that builds CRISPR-based molecular diagnostics and gene-editing platforms for infectious disease and drug-resistant infection testing.

This Startup Deep Dive explains what CrisprBits does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

CrisprBits in Brief

• What it is: CrisprBits is an Indian CRISPR diagnostics biotech company based in Bengaluru.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company develops PathCrisp, a molecular diagnostic platform, as its main commercial product.
• It has a strain engineering platform called EdiCrisp.
• It is developing an AI-powered therapeutics platform called CurieCrisp.
• Funding: Not disclosed in public sources reviewed.

CrisprBits Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is CrisprBits?

CrisprBits operates in the CRISPR diagnostics biotech space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to CrisprBits.

• The company develops PathCrisp, a molecular diagnostic platform, as its main commercial product.
• It has a strain engineering platform called EdiCrisp.
• It is developing an AI-powered therapeutics platform called CurieCrisp.
• It works on faster tests for drug-resistant infections.

The Origin Story of CrisprBits

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Vijay Chandru, Sunil Arora, Rajeev Kohli, Bharat Jobanputra, Aditya Sarda.
• The company was founded in 2020 by five people described as BITS Pilani alumni.
• It was initially incubated at C-CAMP in Bengaluru.
• Its antimicrobial resistance work won AMR-Quest 2023, run by C-CAMP.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the CRISPR diagnostics biotech sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2020: company founded.
• 2023: won AMR-Quest, an antimicrobial resistance challenge.
• January 2025: opened a CRISPR gene editing and diagnostics research and innovation centre in Bengaluru.
• November 2025: reported $3 million pre-Series A round.

CrisprBits Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Reported: $3 million pre-Series A in November 2025 at a $12 million valuation, led by Spectrum Impact, the family office of Rajendra Gogri, with existing investors and new backers from the HBL Engineering promoter family.

How Does CrisprBits Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• The company sells molecular diagnostic tests built on its PathCrisp platform.

The Numbers: CrisprBits Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Audited revenue, profit and loss figures for CrisprBits were not available in the public sources reviewed.
• Readers can check the company’s filings with the Registrar of Companies for the latest financial statements.

Market Opportunity for CrisprBits

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• The company plans to expand into African and Latin American markets.

Technology and Product at CrisprBits

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• CRISPR-based diagnostics (PathCrisp), strain engineering (EdiCrisp) and an AI-powered therapeutics platform (CurieCrisp).

Team and Culture at CrisprBits

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Co-founders include Dr. Vijay Chandru, Sunil Arora, Dr. Rajeev Kohli, Bharat Jobanputra and Aditya Sarda.

CrisprBits Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of CrisprBits vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for CrisprBits

• The company is early stage, having raised a pre-Series A round, with commercial diagnostics still being scaled.
• Its AI therapeutics platform is still in development.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

CrisprBits Growth Outlook: What to Watch

• Plans to advance EdiCrisp and develop CurieCrisp.
• Plans to expand into African and Latin American markets.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether CrisprBits can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where CrisprBits Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for CrisprBits

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for CrisprBits.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from CrisprBits

Studying a company in the CRISPR diagnostics biotech space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about CrisprBits.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate CrisprBits as a Startup

• Customer clarity: Can CrisprBits name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

CrisprBits is part of India’s growing CRISPR diagnostics biotech ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

CrisprBits FAQs: Frequently Asked Questions

What is CrisprBits?

CrisprBits is a biotech startup based in Bengaluru, India, that builds CRISPR-based molecular diagnostics and gene-editing platforms for infectious disease and drug-resistant infection testing. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded CrisprBits?

CrisprBits was founded by Vijay Chandru, Sunil Arora, Rajeev Kohli, Bharat Jobanputra, Aditya Sarda, and the company reports a founding year of 2020.

How much funding has CrisprBits raised?

No reliable total funding figure is disclosed in the public sources reviewed. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does CrisprBits make money?

CrisprBits earns revenue from its CRISPR diagnostics biotech products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of CrisprBits?

Competitors of CrisprBits depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for CrisprBits?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: YourDOST — YourDOST: online counselling for colleges and corporates | NirogStreet — NirogStreet: Ayurveda platform with Rs 66 Cr FY24 revenue. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.